Evidence map›Paper›PMID 40775360›Full record

ArticleOrphanet journal of rare diseases2025

Genetic evaluation of five patients with ROHHAD-NET using whole genome sequencing and optical genome mapping.

N van Engelen, H M van Santen, F van Dijk, M M Kleisman, J H M Merks, A Y N Schouten-van Meeteren, E J Kamping, K Neveling, A Hoischen, M C J Jongmans and 1 more

Abstract readCase Reports
In one paragraph

Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

N van EngelenPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
H M van SantenPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
F van DijkPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
M M KleismanPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
J H M MerksPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
A Y N Schouten-van MeeterenPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
E J KampingDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
K NevelingDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
A HoischenDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
M C J JongmansPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
R P KuiperPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. r.kuiper@prinsesmaximacentrum.nl.ORCID http://orcid.org/0000-0003-4928-3809

Funding

Stichting Kinderen Kankervrij Stichting Kinderen Kankervrij
6 · The paper itself

Abstract

backgroundRapid-onset obesity, hypothalamic dysfunction, hypoventilation, autonomic dysregulation (ROHHAD) and neuroendocrine tumor (NET) is a very rare condition with an unknown etiology. While various potential causes have been hypothesized, including genetic and paraneoplastic autoimmune mechanisms, no definitive cause has been identified to date. This study aimed to explore whether patients with ROHHAD-NET share an underlying heritable genetic etiology.

resultsWe identified five female patients clinically suspected of having ROHHAD(-NET); among them in two patients a NET was found: a ganglioneuroma and a low grade cerebellar ganglion cell tumor with BRAF mutation. To identify potential pathogenic germline genomic variants, whole genome sequencing (WGS) was performed on germline DNA from all five patients, including four patient-parent trios. Furthermore, optical genome mapping (OGM) was performed for two patients to detect germline structural variants (SVs). Rare single nucleotide variants (SNVs) and small insertions/deletions (InDels) were identified through WGS and rare SVs affecting (non)-coding or regulatory regions were analyzed using both WGS and OGM. We explored a de novo, inherited autosomal dominant and autosomal recessive inheritance scenario. However, no candidate variants in a recurrently affected gene locus or genomic region were identified in two or more patients.

conclusionOur comprehensive genome-wide data analysis did not reveal evidence of a monogenetic cause for ROHHAD-NET. Whereas these findings do not exclude a genetic etiology for ROHHAD-NET, they strengthen the hypothesis of an autoimmune origin for symptoms of ROHHAD.

Indexed as

Autonomic Nervous System DiseasesHypothalamic DiseasesNeuroendocrine TumorsObesityWhole Genome SequencingAdultChromosome MappingFemaleHumansPolymorphism, Single NucleotideGermlineOptical genome mappingROHHAD-NETWhole genome sequencing

Identifiers

PMID40775360
PMCPMC12333276

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.